KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EBT: 2010-2025

Historic EBT for Rigel Pharmaceuticals (RIGL) over the last 14 years, with Sep 2025 value amounting to $27.6 million.

  • Rigel Pharmaceuticals' EBT rose 122.37% to $27.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.3 million, marking a year-over-year increase of 2846.02%. This contributed to the annual value of $18.4 million for FY2024, which is 173.20% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' EBT is $27.6 million, which was down 53.95% from $60.0 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' EBT ranged from a high of $60.0 million in Q2 2025 and a low of -$27.4 million during Q1 2022.
  • For the 3-year period, Rigel Pharmaceuticals' EBT averaged around $8.4 million, with its median value being $737,000 (2023).
  • Its EBT has fluctuated over the past 5 years, first slumped by 166.50% in 2022, then surged by 5,923.50% in 2025.
  • Rigel Pharmaceuticals' EBT (Quarterly) stood at -$22.7 million in 2021, then soared by 106.17% to $1.4 million in 2022, then slumped by 47.39% to $737,000 in 2023, then surged by 1,965.40% to $15.2 million in 2024, then spiked by 122.37% to $27.6 million in 2025.
  • Its EBT stands at $27.6 million for Q3 2025, versus $60.0 million for Q2 2025 and $11.5 million for Q1 2025.